cp wire

CP Wire Articles

  • The neural stem cell line into APP/PS1 mice that carry genes bearing mutations associated with onset of AD in humans
  • NSI-532.IGF1 is a second-generation cell therapy candidate that... read more
Thu, 10/25/18 - 09:48 am
  • The FDA previously granted ruxolitinib Breakthrough Therapy Designation for the treatment of acute GVHD
  • Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi (... read more
Thu, 10/25/18 - 09:33 am
  • Xofluxa is a single-dose one-time treatment compared to Tamiflu's twice daily for five day regimen
  • In two trials, patients taking Xofluxa had a shorter duration of flu symptoms... read more
Wed, 10/24/18 - 12:39 pm
The 18th Annual Temperature Controlled Logistics Conference will bring together supply chain, logistics and quality experts from around the globe to experience four days of ‘unmissable’... read more
Wed, 10/24/18 - 12:30 pm
  • Zanubrutinib demonstrated a high overall response rate of 80 percent
  • Zanubrutinib was recently granted Fast Track Designation by the US FDA for Waldenström macroglobulinemia (WM)... read more
Wed, 10/24/18 - 11:53 am
  • 60.3% of all randomised ustekinumab-treated patients who entered the long-term extension study were in clinical remission at week 152
  • Of those patients who were naïve to TNF... read more
Wed, 10/24/18 - 09:45 am

TP Therapeutics announced on 10/24/18 a global collaboration agreement to develop and commercialize a next-generation sequencing (NGS) companion diagnostic (CDx) for repotrectinib, TP... read more

Wed, 10/24/18 - 09:30 am
  • Bain Capital committed $350 million to the company
  • Pfizer is contributing a portfolio of assets that includes three clinical-stage compounds

Bain Capital, LP and... read more

Tue, 10/23/18 - 10:14 am
  • OMS721 also has orphan status for two other conditions
  • OMS721 is Omeros’ lead human MASP-2 antibody
  • The drug was awarded fast track designation for the treatment of patients... read more
Tue, 10/23/18 - 09:43 am
  • Glucagon is the standard of care for treating severe hypoglycemia
  • Mild to moderate hypoglycemia occurs monthly and severe hypoglycemia can occur several times per year
  • The... read more
Tue, 10/23/18 - 09:24 am

Seres Therapeutics, Inc. (Nasdaq:MCRB) announced on 10/22/18 the appointment of Kevin Horgan, M.D., as Executive Vice President and Chief Medical Officer. Dr. Horgan will lead Seres’ clinical... read more

Mon, 10/22/18 - 05:29 pm
  • Pamiparib is currently in Phase 3 trials globally and in China as a monotherapy
  • Of 23 patients with solid tumors, Ten had a best response of stable disease; four patients had a best... read more
Mon, 10/22/18 - 10:01 am
  • In the Tumor Treating Fields plus gemcitabine cohort, progression free survival and overall survival were each more than double those of the gemcitabine-treated historical control
  • ... read more
Mon, 10/22/18 - 09:47 am
  • The Index is a measurement meant to assess the extent of microbiome restoration following microbiota based therapy
  • Rebiotix is developing two microbiota based formulations to treat... read more
Mon, 10/22/18 - 09:31 am

TP Therapeutics announced on 10/19/18 its completion of an $80 million round of mezzanine financing. Foresite Capital and venBio Partners led the investment syndicate, with participation from... read more

Fri, 10/19/18 - 09:29 am

Vertex Pharmaceuticals (Europe) announced on 10/19/18 that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO®(... read more

Fri, 10/19/18 - 09:13 am

Takeda Pharmaceutical Company Limited (TSE: 4502) announced on 8/19/18 that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed... read more

Fri, 10/19/18 - 09:05 am

Symberix announced on 10/18/18  has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), entered into a Research Collaboration... read more

Thu, 10/18/18 - 12:33 am

LNC Therapeutics announced on 10/15/18 that it has signed an exclusive license agreement with Cornell University (Ithaca, NY, USA) for its Christensenella patent family.

Christensenella is... read more

Wed, 10/17/18 - 11:38 pm


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.